Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
The offline store launch will complement the E-commerce website in building a rich consumer shopping experience
According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
It is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
The approval is for Cytomegalovirus, a type of Herpes virus
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Subscribe To Our Newsletter & Stay Updated
